This website is intended for Healthcare Professionals. If you are not a Healthcare Professional please click here
Prescribing
Information

Patients with low inspiratory ability can use the Respimat Inhaler

How to use the Respimat® inhaler every day

Watch videos and read more about how to use your RESPIMAT® inhaler

Watch Video

Respimat inhaler
EXPLORE

EXPLORE

respimat seperator

The innovative technology generates the unique mist

In an in vitro model, Respimat® delivers higher flow rates for less inspiratory effort1

1. Ciciliani A et al. International Journal of COPD 2017:12:1565–1577.

respimat seperator

Inspiratory effort vs. flow rate achieved with different inhalers

With the Respimat® inhaler, patients take a slow, deep breath to get the medication deep into their lungs

Inspiratory effort vs. flow rate graph

Adapted from Ciciliani A, et al. 20171

Breezhaler® is a registered trademark of Novartis, Diskus® (Accuhaler®) is a registered trademark of GSK, Ellipta® is a registered trademark of GSK, Genuair® is a registered trademark of AstraZeneca, Turbohaler® is a registered trademark of AstraZeneca.

COPD, chronic obstructive pulmonary disease

* Inspiratory flow rates of COPD patients were simulated taking into account the different flow resistances of the inhalers1

† Recommended inspiratory flow rates are specific to each device. Check recommended flow rates with marketing authorisation holder

1. Ciciliani A et al. International Journal of COPD 2017:12:1565–1577.

respimat seperator

Dose to the lungs

An in vitro experimental model (using simulations of patients with very severe COPD) to illustrate whole lung deposition with different dry powder inhalers and Respimat®1

In vitro experimental model graph

Breezhaler® is a registered trademark of Novartis, Genuair® is a registered trademark of AstraZeneca, Ellipta® is a registered trademark of GSK. Experimental data given for throat deposition & dose to the lung. CFD simulation data presenting groupings of the following airway generations: trachea-G4, G5-G14, G15-20, G21-alveoli.

*Vilanterol and fluticasone were measured separately when delivered from a nominal dose, delivered as a combination of vilanterol and fluticasone from the Ellipta® device. Vilanterol and fluticasone are not licensed as monotherapy agents through the Ellipta® device.

1. Ciciliani A et al. International Journal of COPD 2017:12:1565–1577.

respimat seperator

How can the carbon footprint of inhalers be compared to driving a car?

The carbon footprint of a pMDI (ipratropium) and Respimat®, used with one cartridge and six cartridges, have been compared with that of an average petrol car.2,3,4

For approx. 200 puffs of ipratropium in a pMDI...

01.

pMDI (ipratropium) carbon footprint for 200 dose inhaler

= driving up to 108.6km

02.

Original disposable Respimat® carbon footprint when 1 inhaler is used with 1 cartridge

The product carbon footprint of the original disposable Respimat® is approximately 20 times smaller than that of pMDIs1

= driving up to 5.1km

03.

Respimat® re-usable carbon footprint when 1 inhaler is used with 6 cartridges

Using Respimat with 6 cartridges reduces the overall product carbon footprint by 71% vs using the inhaler with 1 cartridge.2

= driving up to 1.5km

scroll car respimat wind turbine respimat wind turbine respimat wind turbine respimat boat respimat ferris wheel
  • 2. Hansel M et al. Adv Ther. 2019;36(9):2487–92.
  • 3. Boehringer Ingelheim Data on File SPI19-09a.
  • 4. Department for Business, Energy & Industrial Strategy. Greenhouse Gas Conversion 2019 Methodology Paper for Emission Factors Final Report. Available at: 2019_Green-house-gas-reporting-methodology.pdf (accessed October 2020).
respimat seperator

Frequently asked questions

  • The patient may have been prescribed a refill cartridge and this should be used together with the inhaler. Each inhaler can be used with up to 6 refill cartridges
  • Not to throw the Respimat® re-usable inhaler away when the cartridge is empty.
  • The cartridge should be replaced when the indicator changes colour to red with a white arrow indicating that the cartridge is empty.
  • To get a new prescription when the dose counter changes colour to yellow

Respimat® re-usable is available as a single pack (one Respimat® re-usable inhaler plus one cartridge) and a single refill pack (one cartridge). One cartridge contains 60 puffs (30 medicinal doses).

Each re-usable inhaler may be used with up to six cartridges, after which time a new Respimat® re-usable inhaler pack should be prescribed.
There is an option within prescribing systems which allows a prescriber to choose refills.

Yes. When designing the Respimat® re-usable, only a few secondary components of the Respimat® inhaler, such as the dose indicator and the length of the body, had to be modified or added. Delivered dose (DD) and particle size distribution (PSD) of the Respimat® re-usable inhaler were compared with data from a disposable Respimat®. Performance, in terms of delivered dose and fine particle dose, was unchanged. The delivered doses over nine cartridges were also stable and consistently within the upper and lower limits of the reference inhaler.

The Respimat® re-usable is licenced for use with up to six cartridges.

Boehringer Ingelheim simplified handling, improved readability of the dose indicator and redesigned the Respimat® for re-use with multiple cartridges based on patient and physician feedback. The Respimat® re-usable also offers the potential to reduce environmental impact from re-use with up to six cartridges.

PC-GB-100902 V1 - October 2020
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (Freephone) or PV_local_uk_ireland@boehringer-ingelheim.com
The information on this website has been created by Boehringer Ingelheim. For product information, including patient leaflets and summary of product characteristics, please see Product Information section.
PC-GB-100901 V1 - October 2020